These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30104245)

  • 21. Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
    Heiler S; Lötscher J; Kreuzaler M; Rolink J; Rolink A
    Front Immunol; 2018; 9():656. PubMed ID: 29670626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells.
    Bayer AL; Lee JY; de la Barrera A; Surh CD; Malek TR
    J Immunol; 2008 Jul; 181(1):225-34. PubMed ID: 18566388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-2 induces conformational changes in its preassembled receptor core, which then migrates in lipid raft and binds to the cytoskeleton meshwork.
    Pillet AH; Lavergne V; Pasquier V; Gesbert F; Thèze J; Rose T
    J Mol Biol; 2010 Nov; 403(5):671-92. PubMed ID: 20816854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases.
    Guex-Crosier Y; Raber J; Chan CC; Kriete MS; Benichou J; Pilson RS; Kerwin JA; Waldmann TA; Hakimi J; Roberge FG
    J Immunol; 1997 Jan; 158(1):452-8. PubMed ID: 8977222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-10 produced by induced regulatory T cells (iTregs) controls colitis and pathogenic ex-iTregs during immunotherapy.
    Schmitt EG; Haribhai D; Williams JB; Aggarwal P; Jia S; Charbonnier LM; Yan K; Lorier R; Turner A; Ziegelbauer J; Georgiev P; Simpson P; Salzman NH; Hessner MJ; Broeckel U; Chatila TA; Williams CB
    J Immunol; 2012 Dec; 189(12):5638-48. PubMed ID: 23125413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
    Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-2/Anti-Interleukin-2 Immune Complex Attenuates Cardiac Remodeling after Myocardial Infarction through Expansion of Regulatory T Cells.
    Zeng Z; Yu K; Chen L; Li W; Xiao H; Huang Z
    J Immunol Res; 2016; 2016():8493767. PubMed ID: 27144181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fine tuning subsets of CD4
    Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
    Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor-engineered regulatory T lymphocytes: promise for immunotherapy of autoimmune disease.
    Yi L; Weifan Y; Huan Y
    Cytotherapy; 2019 Sep; 21(9):925-934. PubMed ID: 31105041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.
    Graßhoff H; Comdühr S; Monne LR; Müller A; Lamprecht P; Riemekasten G; Humrich JY
    Front Immunol; 2021; 12():648408. PubMed ID: 33868284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bifidobacterium infantis attenuates colitis by regulating T cell subset responses.
    Zuo L; Yuan KT; Yu L; Meng QH; Chung PC; Yang DH
    World J Gastroenterol; 2014 Dec; 20(48):18316-29. PubMed ID: 25561798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
    Sharma M; Khong H; Fa'ak F; Bentebibel SE; Janssen LME; Chesson BC; Creasy CA; Forget MA; Kahn LMS; Pazdrak B; Karki B; Hailemichael Y; Singh M; Vianden C; Vennam S; Bharadwaj U; Tweardy DJ; Haymaker C; Bernatchez C; Huang S; Rajapakshe K; Coarfa C; Hurwitz ME; Sznol M; Hwu P; Hoch U; Addepalli M; Charych DH; Zalevsky J; Diab A; Overwijk WW
    Nat Commun; 2020 Jan; 11(1):661. PubMed ID: 32005826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory T cells: magic bullets for immunotherapy?
    Frey O; Bräuer R
    Arch Immunol Ther Exp (Warsz); 2006; 54(1):33-43. PubMed ID: 16642255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of antigen-specific Treg cells in treating autoimmune uveitis via bystander suppressive pathways without compromising anti-tumor immunity.
    Chen Z; Zhang T; Kam HT; Qiao D; Jin W; Zhong Y; Zhou M; Zhou H; Chong WP; Chen W; Chen J
    EBioMedicine; 2021 Aug; 70():103496. PubMed ID: 34280776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilizing human regulatory T cells for tolerance inducing immunotherapy.
    He X; Koenen HJ; Slaats JH; Joosten I
    Immunotherapy; 2017 Aug; 9(9):735-751. PubMed ID: 28771099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Rα(-/-) mice.
    Yao Y; Yang W; Yang YQ; Ma HD; Lu FT; Li L; Tao YY; Tsuneyama K; Zhang W; Friedman S; Gershwin ME; Lian ZX
    J Autoimmun; 2014 Jun; 51():99-108. PubMed ID: 24651036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.
    Su EW; Moore CJ; Suriano S; Johnson CB; Songalia N; Patterson A; Neitzke DJ; Andrijauskaite K; Garrett-Mayer E; Mehrotra S; Paulos CM; Doedens AL; Goldrath AW; Li Z; Cole DJ; Rubinstein MP
    Sci Transl Med; 2015 Oct; 7(311):311ra170. PubMed ID: 26511507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
    Levin AM; Bates DL; Ring AM; Krieg C; Lin JT; Su L; Moraga I; Raeber ME; Bowman GR; Novick P; Pande VS; Fathman CG; Boyman O; Garcia KC
    Nature; 2012 Mar; 484(7395):529-33. PubMed ID: 22446627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.